Introduction
============

Basal-bolus insulin therapy is an ideal regimen for improving uncontrolled hyperglycemia in patients with diabetes mellitus.[@b1-dddt-8-391] Prandial premixed insulin therapy (PPT), injected three times a day, is also effective for glycemic control in type 2 diabetics.[@b2-dddt-8-391]--[@b9-dddt-8-391] Further, PPT is convenient for patients, because it requires only a single insulin preparation. However, some subjects receiving insulin therapy prefer not to inject insulin before lunch, because they are often away from home during the daytime. This problem is solely attributable to convenience, but may also affect adherence to the insulin injection regimen and quality of life for patients.

The position statement published by the American Diabetes Association and the European Association for the Study of Diabetes recommends basal insulin injection once daily as the initial insulin regimen for patients with type 2 diabetes mellitus who have high glycated hemoglobin (HbA~1c~) levels (≥9.0%) despite treatment with oral antihyperglycemic agents.[@b1-dddt-8-391] If glycemic control is not achieved by basal insulin therapy, a basal plus mealtime insulin regimen consisting of 1--3 injections of rapid-insulin analogs can be considered.[@b1-dddt-8-391] Basal plus two times bolus insulin therapy (B2B) does not require injection before lunch, so patients' quality of life may be preserved even though insulin preparations are injected three times daily, similar to PPT.

As of February 2014, there were no studies assessing the effectiveness of switching from PPT to B2B. Therefore, we tested the hypothesis that B2B (insulin glargine plus insulin glulisine before breakfast and dinner) would show noninferiority in terms of glycemic control and quality of life when compared with PPT in patients with type 2 diabetes mellitus who want to be able to avoid injecting insulin before lunch.

Patients and methods
====================

Twenty-eight outpatients with type 2 diabetes mellitus receiving PPT and who visited the Department of Diabetes, Metabolism and Kidney Disease at Edogawa Hospital between September 2012 and August 2013 were eligible for this 16-week prospective trial. Physicians in this department treat more than 2,000 patients with diabetes mellitus each year.[@b10-dddt-8-391]--[@b12-dddt-8-391] The criteria for enrollment were type 2 diabetes treated with PPT using 50/50 premixed insulin (Humalog^®^ Mix 50, Eli Lilly Japan KK, Kobe, Japan: 50% insulin lispro protamine suspension and 50% insulin lispro or NovoRapid^®^ 50 Mix, Novo Nordisk Pharma Ltd, Kanagawa, Japan: 50% protamine cocrystallized insulin aspart and 50% insulin aspart) for at least 2 months and a preference to discontinue insulin injection before lunch, based on an interview conducted at the hospital visit. All patients who met these criteria were included in the study. Diabetes mellitus was diagnosed based on the criteria published by the Japan Diabetes Society.[@b13-dddt-8-391] No individuals with positive antiglutamic acid decarboxylase antibodies were identified. The initial doses of insulin glargine (Lantus^®^, Sanofi KK, Tokyo, Japan) and insulin glulisine (Apidra^®^, Sanofi KK) for B2B were determined based on the total dose of premixed insulin being used at entry to the study. A half dose of the total premixed insulin was used as insulin glargine once daily before breakfast or dinner. The other half was divided into two equal doses of insulin glulisine for injection twice daily, before breakfast and dinner. Registered diabetologists were allowed to adjust subsequent doses of insulin at each hospital visit. If oral antihyperglycemic agents were being used at the start of the study, the doses of these agents were maintained throughout the trial.

The Diabetes Treatment Satisfaction Questionnaire (DTSQ) was administered at the start of the study and again 16 weeks later in order to assess the influence of treatment with insulin on the patient's quality of life.[@b14-dddt-8-391],[@b15-dddt-8-391] Treatment satisfaction was estimated by scoring on questions 1, 4, 5, 6, 7, and 8 of the DTSQ. Perceived hyperglycemia and hypoglycemia were expressed as the scores on questions 2 and 3, respectively.

All patients received an explanation of the protocols to be performed and then gave their consent to inclusion in this trial. This study was conducted according to the principles expressed in the Declaration of Helsinki. The ethics committee of Edogawa Hospital approved the study protocol.

Twenty-seven patients (mean age 62±16 years; 19 males and eight females; mean duration of diabetes mellitus, 14±8 years; mean duration on insulin treatment, 48±46 months; mean duration of treatment with PPT using 50/50 premixed insulin, 22±24 months) completed the study ([Table 1](#t1-dddt-8-391){ref-type="table"}). Data were excluded for one patient who wished to suspend insulin injections during the study period and withdrew. Seventeen and ten patients, respectively, were receiving PPT (Humalog Mix 50 and NovoRapid 50 Mix) before the study. Answers to the DTSQ were obtained from 25 and 21 subjects at the start and end of the study, respectively.

Statistical analysis
--------------------

All data are shown as the mean ± standard deviation. Analysis of variance was used for between-group comparisons of continuous variables. The paired *t*-test was used to determine whether there were any differences in HbA~1c~, body weight, body mass index, serum lipid concentrations, or DTSQ scores at the end of the study when compared with baseline values. A least-squares model was used to determine the relationship between HbA~1c~ levels, DTSQ scores, and patient clinical characteristics. Differences with values of *P*\<0.05 (two-tailed) were considered to be statistically significant. JMP version 8.0.1 software (SAS Institute, Cary, NC, USA) was used to perform all analyses.

Results
=======

The clinical characteristics of the patients during the study period are shown in [Table 2](#t2-dddt-8-391){ref-type="table"}. Insulin dose, body weight, and body mass index were not significantly different between baseline and the end of the study. HbA~1c~ and serum lipid levels also did not change significantly. The change in HbA~1c~ (ΔHbA~1c~) was −0.1±1.4 points, and improvement was found at the end of the study compared with baseline in nine (33%) subjects. DTSQ scores reflecting treatment satisfaction, perceived hyperglycemia, and perceived hypoglycemia were not significantly different between the start and end of the study. No episodes of severe hypoglycemia, defined as any symptomatic hypoglycemic event that required assistance by another individual, occurred during the study period.

The ΔHbA~1c~ showed a significant negative correlation with baseline HbA~1c~ ([Figure 1A](#f1-dddt-8-391){ref-type="fig"}), but was not associated with patient age, gender, duration of diabetes, body weight, body mass index, serum lipid concentrations, or type of premixed insulin used before the study. The correlation between ΔHbA~1c~ and baseline HbA~1c~ did not change, even after adjusting for age, sex, disease duration, body mass index, and dose of total insulin at baseline. The ΔHbA~1c~ was significantly lower in patients with a baseline HbA~1c~ \>8.0% than in those with baseline HbA~1c~ ≤8.0% (−0.9±2.0 points versus 0.3±0.6 points, *P*=0.02), as shown in [Figure 1B](#f1-dddt-8-391){ref-type="fig"}.

[Table 3](#t3-dddt-8-391){ref-type="table"} shows a comparison of baseline DTSQ scores divided by baseline HbA~1c~ between the two groups. The baseline DTSQ score reflecting treatment satisfaction was not significantly different between the groups for patients with a baseline HbA~1c~ \>8.0% and those with a baseline HbA~1c~ ≤8.0%. The DTSQ score reflecting perceived hyperglycemia was significantly higher in the group with a baseline HbA~1c~ \>8.0%, whereas the score for perceived hypoglycemia did not differ significantly between the two groups. The change in DTSQ score reflecting treatment satisfaction was significantly greater in patients whose HbA~1c~ level was improved at the end of the study than in those who showed no significant improvement ([Table 4](#t4-dddt-8-391){ref-type="table"}). The change in DTSQ score reflecting treatment satisfaction also showed a significant negative correlation with ΔHbA~1c~ (*r*=−0.61, *P*\<0.01).

Discussion
==========

PPT using 50/50 premixed insulin is widely used in the treatment of type 2 diabetes mellitus,[@b2-dddt-8-391]--[@b8-dddt-8-391] although this regimen does not demonstrate noninferiority compared with basal-bolus insulin therapy.[@b2-dddt-8-391],[@b3-dddt-8-391] However, PPT using 50/50 premixed insulin[@b4-dddt-8-391]--[@b6-dddt-8-391] or biphasic insulin aspart, consisting of 30% rapid-acting insulin aspart and 70% protaminated insulin aspart,[@b9-dddt-8-391] has been shown to be more effective in controlling blood glucose levels than twice-daily administration (before breakfast and dinner) of premixed insulin. An advantage of B2B is that it is unnecessary for patients to inject the insulin before lunch, so their quality of life might be improved compared with that in patients on PPT and basal-bolus insulin therapy regimens. Although it is often difficult to control blood glucose levels before breakfast in subjects treated with PPT using 50/50 premixed insulin,[@b2-dddt-8-391],[@b6-dddt-8-391] this problem can be overcome by increasing the dose of basal insulin in patients treated with B2B. However, blood glucose levels after lunch might be higher in patients treated with B2B, given that these patients do not inject insulin before lunch.

No previous studies have investigated the effectiveness of switching from PPT to B2B. In the present study, the B2B regimen using insulin glargine and insulin glulisine demonstrated noninferiority to PPT with regard to HbA~1c~ level, although the quality of life for patients was not significantly improved. Of note, the B2B regimen was more effective for glycemic control in one third of the subjects previously treated with PPT using 50/50 premixed insulin. Improvement in HbA~1c~ was greater in patients with poor glycemic control (HbA~1c~ \>8.0%) at the start of the study. It has been previously reported that diabetic patients treated with insulin occasionally omit their insulin injection in the real-world clinical setting.[@b16-dddt-8-391],[@b17-dddt-8-391] The improved glycemic control in patients with higher HbA~1c~ levels is considered to have been due to better adherence with insulin injections. We propose that changing from PPT to B2B should be considered for subjects with poor glycemic control. If B2B is not effective, then basal-bolus insulin therapy should be initiated.

DTSQ scores reflecting treatment satisfaction at the start of the study were not significantly different between the groups when divided by their initial HbA~1c~ level. However, treatment satisfaction increased in subjects who showed an improvement in HbA~1c~ at the end of the study. Better adherence with the insulin regimen might have caused both increased treatment satisfaction and the reduction in HbA~1c~.

DTSQ scores were determined by the patients themselves, so scores reflecting perceived hyperglycemia or hypoglycemia did not always match actual blood glucose or HbA~1c~ levels. Even if the level of blood control was poor, the DTSQ score reflecting treatment satisfaction may have been high in some patients who do not worry about their glycemic control. The results of the present study may therefore reflect only a relationship between improved convenience of insulin injection and satisfaction with treatment.

The present study has some limitations that should be kept in mind when interpreting its findings. First, it evaluated preliminary data in a small number of patients. Because the statistical power was insufficient to detect a difference in HbA~1c~ levels between two groups, a further study in a larger group of diabetic patients is necessary. Second, we did not record daily variations in blood glucose by self-monitoring of blood glucose or continuous glucose monitoring. Our study evaluated only the change in HbA~1c~ level. It would be necessary to investigate the daily profile of blood glucose in order to clarify the effects of the B2B regimen in detail. Third, the present study was a one-way protocol, ie, switching from PPT to B2B. A crossover design would be desirable to compare the effectiveness of B2B and PPT.

In conclusion, switching from PPT to B2B was noninferior to PPT alone in terms of HbA~1c~ levels in patients with type 2 diabetes mellitus. B2B should be considered, particularly in subjects whose glycemic control is poor despite PPT.
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![(**A**) Relationship between changes in HbA~1c~ after initiation of B2B (ΔHbA~1c~) and baseline value of HbA~1c~. (**B**) Comparison of ΔHbA~1c~ between subjects with baseline HbA~1c~ ≤8.0% and those with baseline HbA~1c~ \>8.0%.\
**Abbreviations:** B2B, basal plus two times bolus insulin therapy; HbA~1c~, glycated hemoglobin.](dddt-8-391Fig1){#f1-dddt-8-391}

###### 

Clinical characteristics of study subjects

  Number   Age (years)   Sex      Duration of diabetes (years)   BMI (kg/m^2^)   Dose of insulin (units/day)   HbA~1c~ (%)
  -------- ------------- -------- ------------------------------ --------------- ----------------------------- -------------
  1        22            Male     6                              23.6            16                            10.8
  2        30            Male     24                             37.5            26                            9.8
  3        42            Male     8                              23.3            20                            7.4
  4        43            Male     13                             24.0            24                            7.6
  5        44            Male     15                             28.9            42                            10.4
  6        51            Female   0.8                            22.0            22                            6.9
  7        52            Male     17                             24.1            22                            7.1
  8        57            Male     7                              29.4            18                            12.5
  9        58            Male     23                             24.9            40                            8.2
  10       60            Female   14                             22.3            24                            14.5
  11       61            Male     18                             23.8            26                            6.9
  12       61            Female   4                              22.8            12                            7.0
  13       61            Male     11                             26.1            50                            8.0
  14       61            Male     7                              24.4            12                            7.9
  15       62            Male     19                             24.8            26                            6.8
  16       65            Male     14                             19.8            14                            6.9
  17       69            Male     10                             33.4            18                            7.7
  18       70            Female   20                             25.6            40                            8.0
  19       71            Female   12                             28.7            42                            8.1
  20       74            Male     29                             22.5            44                            8.1
  21       76            Female   9                              24.0            26                            6.9
  22       76            Male     19                             30.6            40                            7.7
  23       77            Female   16                             20.7            32                            7.5
  24       78            Male     34                             23.6            12                            7.7
  25       79            Male     15                             27.5            30                            8.1
  26       80            Male     0.3                            26.3            18                            7.0
  27       83            Female   9                              24.6            28                            9.5

**Abbreviations:** BMI, body mass index; HbA~1c~, glycated hemoglobin.

###### 

Changes in clinical characteristics during the study period

                                      Baseline    16 weeks    *P*-value
  ----------------------------------- ----------- ----------- -----------
  Dose of total insulin (units/day)   26.8±11.0   25.8±9.6    0.33
  Dose of basal insulin (units/day)   13.4±5.5    13.6±5.8    0.80
  Body weight (kg)                    69.3±15.1   69.6±14.8   0.38
  Body mass index (kg/m^2^)           25.5±3.9    25.6±3.9    0.31
  HbA~1c~ (%)                         8.3±1.8     8.2±1.1     0.64
  LDL cholesterol (mmol/L)            2.6±0.7     2.6±0.7     0.97
  HDL cholesterol (mmol/L)            1.4±0.4     1.4±0.4     0.28
  Non-HDL cholesterol (mmol/L)        3.3±1.0     3.2±0.8     0.53
  DTSQ score                                                  
   Treatment satisfaction             23.7±7.1    24.5±6.4    0.41
   Perceived hyperglycemia            3.7±1.7     3.6±1.4     0.74
   Perceived hypoglycemia             1.7±1.9     1.9±1.7     0.70

**Abbreviations:** HbA~1c~, glycated hemoglobin; DTSQ, Diabetes Treatment Satisfaction Questionnaire; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

###### 

Comparison of baseline DTSQ scores between the groups divided by baseline HbA~1c~ level

                             Baseline HbA~1c~ (%)              
  -------------------------- ---------------------- ---------- --------
  Baseline DTSQ score                                          
   Treatment satisfaction    23.1±5.8               25.5±7.8   0.39
   Perceived hyperglycemia   2.9±1.3                4.7±1.3    \<0.01
   Perceived hypoglycemia    1.9±1.8                1.3±1.9    0.41

**Abbreviations:** HbA~1c~, glycated hemoglobin; DTSQ, Diabetes Treatment Satisfaction Questionnaire.

###### 

Comparison of changes in DTSQ scores between groups divided by change of HbA~1c~ after initiation of B2B

                             HbA~1c~               
  -------------------------- ---------- ---------- ------
  Change in DTSQ score                             
   Treatment satisfaction    2.7±3.6    −0.8±3.5   0.04
   Perceived hyperglycemia   −0.6±1.4   0.3±1.1    0.17
   Perceived hypoglycemia    0.7±1.5    −0.3±1.8   0.23

**Abbreviations:** B2B, basal plus two times bolus insulin therapy; HbA~1c~, glycated hemoglobin; DTSQ, Diabetes Treatment Satisfaction Questionnaire.
